Rallybio Presents Data Demonstrating ENPP1 Inhibition As A Therapeutic Approach For Later-Onset Hypophosphatasia Presented At The American Society For Bone And Mineral Research 2024 Annual Meeting
Rallybio Presents Data Demonstrating ENPP1 Inhibition As A Therapeutic Approach For Later-Onset Hypophosphatasia Presented At The American Society For Bone And Mineral Research 2024 Annual Meeting
Rallybio展示数据，证明ENPP1抑制作为治疗后发性低磷酸盐血症的治疗方法，展示于美国骨科与矿物研究学会2024年年会。
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. ASBMR is being held September 27 – 30, 2024 in Toronto, Canada.
Rallybio公司（纳斯达克股票代码：RLYB）是一家临床阶段的生物技术公司，将科学进展转化为治疗罕见疾病患者的革命性疗法，并宣布今天在美国骨质与矿物研究学会（ASBMR）2024年度会议上展示了关于ENPP1抑制作为治疗低磷酸酶骨软化症（HPP）患者的治疗方法的非临床数据。ASBMR会议将于2024年9月27日至30日在加拿大多伦多举行。